Angiotensin (1-12) and Hypertension in the Elderly
血管紧张素 (1-12) 与老年人高血压
基本信息
- 批准号:10370035
- 负责人:
- 金额:$ 23.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-30 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:ACE2AdherenceAdultAffinityAgeAgingAldosteroneAmino Acid SequenceAngiotensin IIAngiotensin II ReceptorAngiotensin-Converting Enzyme InhibitorsAngiotensinogenAngiotensinsAnimal ExperimentationAnimalsAntibodiesAntibody TherapyAntihypertensive AgentsAtrial FibrillationAttenuatedBloodBlood PressureCardiacCardiac MyocytesCardiovascular PhysiologyCardiovascular systemCellsCessation of lifeChymaseClinicalDataDementiaDevelopmentEffectivenessElderlyEngineeringEssential HypertensionEventExclusionFDA approvedFemaleFunctional disorderGenerationsGenesGenomeGoalsGrantHeartHeart DiseasesHeart RateHeart failureHematologic NeoplasmsHigh PrevalenceHormonesHumanHypertensionHypertrophyImmunosuppressionImmunotherapyInbred WKY RatsIndividualInfusion proceduresInjectionsKidneyLeftLeft Ventricular DysfunctionLeft ventricular structureLifeLipidsLisinoprilLiverLong-Term EffectsMalignant NeoplasmsMeasurementMeasuresModelingMonoclonal AntibodiesMorbidity - disease rateMulticenter StudiesMyocardial InfarctionNewly DiagnosedOralOrganPathogenesisPathologicPathway interactionsPatientsPeptidyl-Dipeptidase APharmaceutical PreparationsPlasmaPopulationPrevention strategyPublic HealthRattusRenal functionReninRenin-Angiotensin SystemResearchResidual stateRiskRisk ReductionRoleSerumSiteSolid NeoplasmSprague-Dawley RatsTherapeuticTherapeutic EffectTimeTissuesTransgenic OrganismsVascular remodelingVentricular DysfunctionWorkagedauricular appendagebaseblood pressure regulationcancer therapycardiovascular risk factoreffective therapyefficacy evaluationexperimental studyheart functionhemodynamicshuman old age (65+)hypertension treatmentimprovedin vivoinhibitor/antagonistinnovationmalemedication compliancemild cognitive impairmentmortalitynanobodiesnovelpatient populationpolyclonal antibodypressuretissue processingtreatment adherencetreatment strategyurinaryvalsartan
项目摘要
Project Summary
The burden of high blood pressure, a major public health problem, is aggravated by an aging human
population. A plethora of experimental data points to angiotensin II (Ang II), as the major contributing factor in
the development of hypertension-related target organ damage. Although data suggested that classic RAS
inhibitors exert positive therapeutic benefits multi-center studies of the long-term effects of these drugs on
cardiovascular morbidity and mortality showed an effectiveness similar to other classes of antihypertensive
drugs. Our hypothesis is that cardiac and renal Ang-(1-12), as a primary precursor for non-renin dependent Ang
II generation, may account for the progressive development of pressure-related target organ damage. The major
goal of this project is to evaluate the therapeutic effects of monoclonal antibodies (mABs) and cell penetrating
nanobodies (Nbs) against the human sequence of Ang-(1-12) through combining high efficacy with improve
treatment adherence. Work in progress characterized mAbs against the C-terminus of human Ang-(1-12).
Whole animal hemodynamic experiments provide proof of concept on the ability of in vivo neutralization of Ang-
(1-12). Research will be performed in a humanized model of hypertension engineered by insertion of the human
angiotensinogen (AGT) gene into the genome of Sprague Dawley rats. Research strategies in male and female
transgenic hypertensive rats will combine continuous blood pressure and heart rate recordings with assessment
of plasma levels of Ang-(1-12), Ang I, Ang II, and Ang-(1-7), measurements of plasma renin activity, and serum
aldosterone, and cardiac and renal function variables. These measures to be taken before and at 1 and 4 weeks
after initiation of therapy with either Ang-(1-12) mAbs or nanobodies (NB). The effectiveness of this
immunotherapy in blood pressure control will be further quantified in experiments in which antibodies are given
to transgenic hypertensive rats in combination with lisinopril or valsartan. The proposed highly innovativestudies
will provide a conceptual basis for novel hypertension treatment strategies involving neutralization of Ang-(1-12).
项目摘要
高血压是一个主要的公共健康问题,随着人口老龄化,高血压的负担更加严重
人口。大量的实验数据表明,血管紧张素II(Ang II)是导致高血压的主要因素
高血压相关靶器官损害的发展。尽管数据表明经典的RAS
抑制剂发挥积极的治疗作用这些药物的长期影响的多中心研究
心血管发病率和死亡率显示出与其他类别的降压药相似的疗效
毒品。我们的假设是心脏和肾脏Ang-(1-12)是非肾素依赖型Ang的主要前体
II代,可能是压力相关靶器官损害进行性发展的原因。少校
本项目的目的是评估单抗和细胞穿透的治疗效果。
高效与改进相结合的纳米抗体(NBS)抗Ang-(1-12)人类序列
治疗依从性。正在进行的工作是针对人类Ang-(1-12)的C末端的单抗。
全动物血流动力学实验为血管紧张素转换酶体内中和能力的概念提供了证据。
(1-12)。研究将在人性化的高血压模型中进行,该模型通过植入人类
血管紧张素原(AGT)基因导入SD大鼠基因组。男性和女性的研究策略
转基因高血压大鼠将结合连续血压和心率记录进行评估
血浆Ang-(1-12)、Ang I、Ang II和Ang-(1-7)水平、血浆肾素活性和血清
醛固酮、心脏和肾功能变量。这些措施将在1周前、1周和4周采取
在开始使用Ang-(1-12)单抗或纳米抗体(NB)治疗后。这样做的有效性
控制血压的免疫疗法将在给予抗体的实验中进一步量化。
转基因高血压大鼠联合赖诺普利或valsartan。建议的高度创新研究
将为涉及中和Ang-(1-12)的新型高血压治疗策略提供概念基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CARLOS M FERRARIO其他文献
CARLOS M FERRARIO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CARLOS M FERRARIO', 18)}}的其他基金
Angiotensin (1-12) and Hypertension in the Elderly
血管紧张素 (1-12) 与老年人高血压
- 批准号:
10495233 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
Angiotensin-(1 -12). Novel Pathways for Angiotensin Peptide Formation
血管紧张素-(1 -12)。
- 批准号:
8250036 - 财政年份:2011
- 资助金额:
$ 23.25万 - 项目类别:
Angiotensin-(1 -12). Novel Pathways for Angiotensin Peptide Formation
血管紧张素-(1 -12)。
- 批准号:
8147911 - 财政年份:2010
- 资助金额:
$ 23.25万 - 项目类别:
Angiotensin-(1-7). Novel Pathways for Angiotensin Peptide Formation
血管紧张素-(1-7)。
- 批准号:
7647683 - 财政年份:2009
- 资助金额:
$ 23.25万 - 项目类别:
相似海外基金
Structural Racism, Pharmacy Closures and Disparities in Medication Adherence Among Older Adult Medicare Part-D Beneficiaries
结构性种族主义、药房关闭以及老年人医疗保险 D 部分受益人的药物依从性差异
- 批准号:
10568717 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services
接受部落卫生服务的成年美洲印第安人的药物依从性和心脏代谢控制指标
- 批准号:
10419967 - 财政年份:2022
- 资助金额:
$ 23.25万 - 项目类别:
Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services
接受部落卫生服务的成年美洲印第安人的药物依从性和心脏代谢控制指标
- 批准号:
10592441 - 财政年份:2022
- 资助金额:
$ 23.25万 - 项目类别:
Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients
利用技术提高青少年和年轻肾移植或肝移植受者的药物依从性
- 批准号:
10369750 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients
利用技术提高青少年和年轻肾移植或肝移植受者的药物依从性
- 批准号:
10633248 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients
利用技术提高青少年和年轻肾移植或肝移植受者的药物依从性
- 批准号:
10487516 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
Mhealth for Pre-exposure Prophylaxis Adherence by Young Adult MSM
Mhealth 促进年轻 MSM 遵守暴露前预防
- 批准号:
10228564 - 财政年份:2018
- 资助金额:
$ 23.25万 - 项目类别:
Mhealth for Pre-exposure Prophylaxis Adherence by Young Adult MSM
Mhealth 促进年轻 MSM 遵守暴露前预防
- 批准号:
9347041 - 财政年份:2017
- 资助金额:
$ 23.25万 - 项目类别:
Mindfulness training with HIV-positive youth and adult family members to improve treatment adherence
对艾滋病毒呈阳性的青少年和成年家庭成员进行正念训练,以提高治疗依从性
- 批准号:
9480702 - 财政年份:2016
- 资助金额:
$ 23.25万 - 项目类别:
Mindfulness training with HIV-positive youth and adult family members to improve treatment adherence
对艾滋病毒呈阳性的青少年和成年家庭成员进行正念训练,以提高治疗依从性
- 批准号:
9906853 - 财政年份:2016
- 资助金额:
$ 23.25万 - 项目类别:














{{item.name}}会员




